
Johnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania.
Podcast: Treatment strategies on a long-debated issue, 18 experts reveal what they really do in practice.
Podcast: Treatment strategies on a long-debated issue, 18 experts reveal what they really do in practice. For more on this topic, see

